Magnet Biomedicine’s TrueGlueTM Platform: A Systematic Approach Towards the Discovery of Molecular Glue Inhibitors (MGIs) for Therapeutic Tntervention

• Magnet Biomedicine is a pioneer in the discovery of novel molecular glue inhibitors (MGIs)
• TrueGluesTM can target previously intractable proteins of interest and localize therapeutic effects to disease-relevant tissues
• The presentation will highlight the MagnetBio TrueGlueTM discovery platform and share data from our lead programs

Speakers:

Brian Safina

President & Chief Executive Officer

Magnet Biomedicine